Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) Derived by passage in monkeys

Journal of Virology

Volumn 75, Issue 9, 2001, Pages 4208-4218

  Si, Z ^a   Cayabyab, M ^a   Sodroski, J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ENVELOPE PROTEIN; GLYCOPROTEIN; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY; PROTEIN HXBC2; PROTEIN HXBC2 3.2; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY AFFINITY; ARTICLE; CELL SURFACE; CHIMERA; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; MOLECULAR CLONING; MONKEY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; STRAIN DIFFERENCE; T LYMPHOCYTE ACTIVATION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TRANSFORMED; CELL MEMBRANE; GIANT CELLS; HAPLORHINI; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; NEUTRALIZATION TESTS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0035046931     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.9.4208-4218.2001     Document Type: Article

References (89)

1. Identifcation of the major envelope glycoprotein product of HTLV-III
2. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)
3. Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins
4. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
5. Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2)
6. Core structure of gp41 from HIV envelope glycoprotein
7. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation
8. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
9. Isolation of a new human retrovirus from West African patients with AIDS
10. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates
11. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
12. A soluble form of CD4 (T4) protein inhibits AIDS virus infection
13. Identification of a major co-receptor for primary isolates of HIV-1
14. Conformational transitions in CD4 due to complexation with HIV-envelope glycoprotein gp120
15. The simian immunodeficiency viruses
16. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
17. + cells is mediated by the chemokine receptor CC-CKR-5
18. Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo
19. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIVKB9) passaged in vivo
20. NIH conference. Acquired immunodeficiency syndrome: Epidemiologic, clinical, immunologic, and therapeutic considerations
21. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
22. HIV infection is blocked in vitro by recombinant soluble CD4
23. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex
24. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS
25. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs
26. SIV/HIV-1 chimeric viruses having HIV-1 env gene: A new animal model and a candidate for attenuated live vaccine
27. Species-specific, postentry barriers to primate immunodeficiency virus infection
28. Persistent infection with SIVmac chimeric virus having tat, rev, vpu, env and nef of HIV type 1 in macaque monkeys
29. + T cells and AIDS in pig-tailed macaques
30. Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques
31. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1
32. Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III
33. + lymphocyte depletion in rhesus monkeys
34. The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques
35. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582-Thr) decreases viral neutralization of monoclonal antibodies to the CD4-binding site
36. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
37. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication
38. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants
39. Numbering position in HIV relative to HXB2CG
40. Structure of an HIV-1 gp120 envelope gtycoprotein in complex with the CD4 receptor and a neutralizing antibody
41. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates
42. Importance of membrane fusion mediated by the human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells
43. Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41
44. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells
45. Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III
46. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins
47. Persistent infection of macaques with simian-human immunodeficiency viruses
48. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV)
49. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain
50. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group
51. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive ones
52. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
53. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
54. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes
55. Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains
56. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex
57. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity
58. Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1
59. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120
60. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
61. A role for carbohydrates in immune evasion in AIDS
62. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene
63. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
64. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
65. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients
66. Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC
67. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding
68. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
69. An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface
70. Blocking of HIV-1 infectivity by a soluble secreted form of the CD4 antigen
71. Initial characterization of viral sequences from a SHIV-inoculated pig-tailed macaque that developed AIDS
72. A cell-free stock of simian-human immunodeficiency virus that causes AIDS in pig-tailed macaques has a limited number of amino acid substitutions in both SIVmac and HIV-1 regions of the genome and has altered cytotropism
73. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies
74. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates
75. Atomic structure of a thermostable subdomain of HIV-1 gp41
76. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoproteins conferred by a gp41 amino acid change
77. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein
78. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
79. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody
80. Soluble CD4 molecules neutralize human immunodeficiency virus type 1
81. CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR5
82. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
83. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites
84. Atomic structure of the ectodomain from gp41
85. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope
86. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
87. The antigenic structure of the human immunodefciency virus gp120 envelope glycoprotein
88. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
89. Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo